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ABSTRACT
Information about resistance profile of darunavir (DRV) is scarce in Brazil. Our objectives were to 
estimate the prevalence of DRV resistance mutations in patients failing protease inhibitors (PI) and 
to identify factors associated with having more DRV resistance mutations. All HIV-infected patients 
failing PI-based regimens with genotyping performed between 2007 and 2008 in a referral teaching 
center in São Paulo, Brazil, were included. DRV-specific resistance mutations listed by December 
2008 IAS-USA panel update were considered. Two Poisson regression models were constructed to 
assess factors related to the presence of more DRV resistance mutations. A total of 171 HIV-infected 
patients with available genotyping were included. The number of patients with lopinavir, saquinavir, 
and amprenavir used in previous regimen were 130 (76%), 83 (49%), and 35 (20%), respectively. 
The prevalence of major DRV resistance mutations was 50V: 5%; 54M: 1%; 76V: 4%; 84V: 15%. For 
minor mutations, the rates were 11I: 3%; 32I: 7%; 33F: 23%; 47V: 6%; 54L: 6%; 74P: 3%; 89V: 6%. 
Only 11 (6%) of the genotypes had ≥ 3 DRV resistance mutations. In the clinical model, time of 
HIV infection of > 10 years and use of amprenavir were independently associated with having more 
DRV resistance mutations. In the genotyping-based model, only total number of PI resistance muta-
tions was associated with our outcome. In conclusion, the prevalence of DRV mutations was low. 
Time of HIV infection, use of amprenavir and total number of PI resistance mutations were associ-
ated with having more DRV mutations. 
Keywords: antiretroviral therapy; highly active; HIV protease inhibitors; acquired immunodefi-
ciency syndrome; Brazil.
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INTRODUCTION
Over 90% of people with HIV/AIDS live in de-
veloping countries, where only a minority of 
patients who need treatment has access to first 
and second-line antiretroviral (ARV) drugs. 
Darunavir (DRV) was approved by the 
Food and Drug Administration in June 2006 
for use in treatment-experienced patients.1,2 
Since 2008, DRV was included among the ARV 
drugs available in Brazil,3 a middle-income 
country with a well-structured National Pro-
gram of AIDS, including free access to drugs 
and genotyping. However, information about 
this protease inhibitor (PI) is scarce in our 
setting. The objectives of this study were to 
estimate the prevalence of DRV resistance mu-
tations in patients failing other PIs and to iden-
tify associated factors with having more DRV 
resistance mutations.
PATIENTS AND METHODS
All adult HIV-1-infected patients from the 
AIDS Clinic of School of Medicine, Universi-
dade de São Paulo, a referral teaching center in 
Brazil, with genotyping performed between Jan-
uary 2007 and December 2008, were retrospec-
tively examined. Only patients failing PI-based 
regimes were selected for this analysis. Demo-
graphic, prior treatment exposure and drug 
regimens at the time of failure were recorded. 
Darunavir-specific resistance mutations listed 
by the December 2008 IAS-USA panel update 
were considered.4 They were classified as major 
(I50V, I54M, L76V, and I84V) or minor (V11I, 
V32I, L33F, I47V, L74P). These mutations have 
been mainly derived from information recorded 
from the POWER and DUET trials.5
All data are reported as absolute num-
bers and percentages, as well as mean ± SD. 
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In the clinical model, time of HIV diagnosis of > 10 years 
(RR 2.8, 95% CI 1.6-4.9, p < 0.001) and prior use of amprena-
vir (RR 2.2, 95% CI 1.5-3.3, p < 0.001) were independently as-
sociated with having more DRV resistance mutations. In the 
genotyping-based model, only the total number of PI resis-
tance mutations (RR per increase in one mutation 1.3, 95% CI 
1.2-1.4, p < 0.0001) was associated with our outcome. 
DISCUSSION
In this study, the prevalence of DRV mutations was low. 
Time of HIV infection, use of amprenavir and total number 
of PI resistance mutations were associated with having more 
DRV mutations.
Most genotypes were from patients with a prolonged his-
tory of HIV infection, low CD4+ T cell nadir, triple-class ex-
Table 1. Univariable analysis to identify associated 
variables with DRV-specific resistance mutations
Variable Relative Risk p 
  (95% CI)
Age (per 5 year increase) 1.0 (0.9-1.1) 0.6
Time of HIV diagnosis  
 > 10 years (vs.	≤	10	years)	 3.4	(2.0-5.7)	 <	0.001
AIDS-defining disease 
0.7 (0.5-1.0) 0.06
 
(vs. No)
Nadir CD4 cell count  
 < 100 (vs.	≥	100)	cells/μL	 1.4	(1.0-2.0)	 0.04
CD4 prior to genotyping  
(vs. > 200) cells/µL 
 < 100 cells/µL 1.8 (1.2-2.6) 
0.02
 100-200 cells/µL 0.9 (0.5-1.4) 
Viral load prior to genotyping  
(vs.	≤	10,000	copies/mL) 
 > 100,000 copies/mL 1.0 (0.6-1.7) 
0.8
 10,000-100,000 copies/mL 0.9 (0.6-1.4) 
Number of ARVs previously 
1.2 (1.0-1.5) 0.08
 
used (per increase in one drug)
Number of PI previously used 
1.1 (1.1-1.2) < 0.001
 
(per increase in one PI)
Prior use of APV either last ARV 
2.6 (1.8-3.7) < 0.0001
 
scheme or before (vs. No)
Number of all mutations for PIs  
(per increase in one PI mutation) 1.3 (1.2-1.4) < 0.00001
Comparisons were made using the Student’s t test or Wil-
coxon rank sum tests for continuous variables, and the 
Pearson qui-square or the Fisher’s exact tests for categorical 
variables. We performed two multivariable Poisson models 
assessing factors related to the presence of more DRV muta-
tions: I) a clinical model, including clinical variables only; 
and II) a genotyping-based model, including clinical vari-
ables and the variable “total number of PI resistance muta-
tions”. The values of p < 0.05 were considered statistically 
significant. All statistical analysis was performed using the 
S-Plus 7.0 (Insightful, WA, USA).
RESULTS
A total of 171 HIV-infected patients failing PI-based 
regimens and with available genotyping were included. The 
mean age was 43 ± 8.6 years old and 112 (65%) were male. 
The mean time of HIV diagnosis was 11.5 ± 4.0 years. Most pa- 
tients (n = 114, 68%) had ≥ 10 years of HIV diagnosis. Most 
patients had a history of AIDS-defining diseases (n = 100, 58%).
The mean ± SD of CD4+ T cell count at baseline was 
251 ± 184 cells/mL. Mean CD4+ T cell count nadir 
was 109 ± 93.1 cells/mL. Mean HIV RNA load at the mo-
ment of the failure was 88,538 ± 15,351 copies/mL or 
4.5 ± 0.6 log10 copies/mL. 
Most patients (n = 99, 58%) used at least five antiretroviral 
regimens previously. A group of 141 (82%) patients had used 
non-nucleoside reverse transcriptase inhibitors. The number 
of patients with LPV, SQV, and APV use at any time before 
genotyping (in the last regimen or prior to last regimen) were 
130 (76%), 83 (49%), and 35 (20%), respectively. Patients failing 
lopinavir (n = 93, 54%), atazanavir (n = 56, 33%), saquinavir 
(13, 8%), amprenavir (n = 8, 5%), indinavir (n = 8, 5%), 
nelfinavir (n = 8, 5%), and tipranavir (n = 1, 1%) were identi-
fied to this study. Among these, 16 (9%) patients received regi-
mens with double-boosted protease inhibitors. The prevalence of 
major DRV resistance mutations was 50V: 8 (5%); 54M: 1 (1%); 
76V: 7 (4%); 84V: 26 (15%). For minor DRV resistance muta-
tions, the rates were 11I: 5 (3%); 32I: 12 (7%); 33F: 40 (23%); 47V: 
10 (6%); 54L: 10 (6%); 74P:5 (3%); 89V: 11 (6%). The number of 
mutations for DRV was as follows: No mutation: 89 (52%), one 
mutation: 52 (30%); two mutations: 19 (11%); three mutations: 
4 (2%); four mutations: 2 (1%); and five mutations: 5 (3%). Only 
11 (6%) of the genotypes had ≥ 3 DRV resistance mutations. The 
mean total number of PI resistance mutations was 8.4 ± 4.1. 
The patients with ≥ 3 DRV-specific resistance mutations had a 
mean total number of protease resistance mutations from the 
IAS-USA list of 13.5 ± 1.9, whereas individuals with < 3 DRV-
specific resistance mutations had a mean number of 8.1 ± 4.0 
(p < 0.001). The variables associated with more DRV-specific 
resistance mutations in the univariable analysis were: time of 
HIV diagnosis, nadir CD4 cell count, CD4 prior to genotyp-
ing, number of PI previously used, prior use of amprenavir, 
and total number of mutations for PIs (Table 1).
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PI with a high genetic barrier. Thus, although amprenavir 
and fosamprenavir can select mutational resistance path-
ways to DRV, this drug need multiple specific mutations 
to be substantially compromised. A practical consid-
eration to this observation could be the early discon-
tinuation of a failing regimen containing amprenavir 
or fosamprenavir in order to avoid accumulating resis-
tance that could compromise the future use of DRV. On 
the other hand, a recent study suggests that expected 
increased efficacy of DRV compared to amprenavir in 
PI-experienced patients is most likely a result of higher 
potency rather than unique cross-resistance profile.12 
In conclusion, the prevalence of DRV-specific resis-
tance mutations was low and similar to previous reports 
from developed countries. Time of HIV infection, prior 
use of amprenavir and total number of PI resistance 
mutations were associated with having more DRV resis-
tance mutations. DRV may be an important component 
of a salvage treatment of patients who failed other PI-
based regimens in our setting. Local clinical studies are 
necessary to confirm this finding.
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perienced-patient, and predominant use of ritonavir-boost-
ed PIs when the genotyping was performed. Therefore, the 
population profile included in this study presents the ideal 
scenario to use salvage regimens. 
In the POWER studies, baseline phenotypic suscep-
tibility to DRV was the strongest predictor of virologic 
response.2 However, phenotyping is not available in the 
public health services in Brazil, where the National Geno-
typing Network (RENAGENO) was established in 2001.3 
In the POWER/DUET trials, the virologic response to 
DRV was strongly predicted by the baseline number of 
DRV-specific resistance mutations with the presence 
of ≥ 3 of these mutations associated with a decreased vi-
rologic response.6 The frequency of DRV-specific resis-
tance mutations in our study was low. Only 6% of the gen-
otypes had ≥ 3 DRV-specific resistance mutations. These 
results confirm that DRV constitutes a viable option to 
structure a rescue regimen in multi-experienced HIV-
infected patients failing other PI. The result was similar 
with a Spanish study that evaluated 1,021 genotypes from 
patients failing other PIs and 6.7% of them had ≥ 3 DRV-
specific resistance mutations.7 Other study reported that 
96% of 1,175 PI-treated persons in a Northern California 
clinic population and 99% of 2,744 PI-treated persons 
listed in the Stanford HIV Drug Resistance Database have 
< 3 DRV-specific resistance mutations.8
In the present study, time of HIV infection, prior use 
of amprenavir and total number of PI resistance muta-
tions were associated with having more DRV resistance 
mutations in two independent multivariate models. Few 
studies identified associated factors with the number of 
DRV-specific resistance mutations. A Spanish study iden-
tified that prior fosamprenavir failure, prior saquinavir 
failure, total number of PI resistance mutations and the 
number of prior PIs used were all independently associated 
with having more DRV-specific resistance mutations in the 
multivariate analysis.7 A North American study identified 
in multivariate analysis that the number of DRV resis-
tance-associated mutations depended on the number 
of previous PIs administered and on amprenavir/fosam-
prenavir treatment.8 In contrast to these reports, a sub-
analysis of the POWER 1, 2, and 3 studies concluded that 
prior utilization or resistance to amprenavir at screening 
seemed to have only a minimal effect on the virological 
response to DRV/r at 48-weeks.9 In addition, a study that 
evaluated the efficacy of DRV in twelve patients failing 
PI (5 of them with fosamprenavir) concluded that prior 
failure with this PI had only a minimal impact on the ef-
ficacy to DRV.10 
Amprenavir, fosamprenavir, and DRV are structurally 
related molecules.7 Moreover, the regression coefficients of 
the mutations associated with decreased susceptibility to 
DRV and fosamprenavir are strongly correlated.11 DRV is a 
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